Zhi Tong Cai Jing·2026-02-04 06:40Core Viewpoint - Credit Lyonnais has raised JD Health's (06618) adjusted net profit forecasts for the fiscal years 2026 and 2027 by 1% and 2% respectively, reflecting the recovery in drug sales and profit expansion prospects, while maintaining an "Outperform" rating and a target price of HKD 71 [1] Group 1: Financial Performance - JD Health is expected to maintain growth momentum in the second half of last year, driven by strong performance during the Double Eleven sales event and a surge in flu cases in December, with revenue projected to increase by 24.5% year-on-year to RMB 37.1 billion [1] - The company is anticipated to see adjusted EBIT double year-on-year to RMB 2.1 billion, supported by gross margin expansion and operational leverage [1] - Revenue for 2026 is expected to grow by 16% year-on-year [1]